CSIMarket
 
Actavia Life Sciences Inc   (RASP)
Other Ticker:  
 
 
Price: $0.0077 $-0.01 -56.983%
Day's High: $0.0077 Week Perf: 0.00
Day's Low: $ 0.01 30 Day Perf: -69.2 %
Volume (M): 0 52 Wk High: $ 0.05
Volume (M$): $ 0 52 Wk Avg: $0.02
Open: $0.01 52 Wk Low: $0.01



 Market Capitalization (Millions $) 6
 Shares Outstanding (Millions) 772
 Employees -
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -4
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Actavia Life Sciences Inc
Actavia Life Sciences Inc is a biotechnology company that specializes in developing innovative therapies for various medical conditions. The company focuses on areas such as oncology, neurology, and rare diseases. Actavia Life Sciences aims to improve patient outcomes by discovering and commercializing advanced treatments. They utilize cutting-edge research, technology, and collaborations with academic institutions and industry partners to advance their product pipeline. The company is committed to addressing unmet medical needs and improving the quality of life for patients worldwide.


   Company Address: 5 Penn Plaza New York 10001 NY
   Company Phone Number: 396-4087   Stock Exchange / Ticker: RASP
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Actavia Life Sciences Inc

Actavia Life Sciences Inc Faces Challenges in First Quarter of 2024

In the first quarter of 2024, Actavia Life Sciences Inc (RASP) reported balanced books of $0.00 per share, showing no change from the previous year but a slight improvement from the prior reporting period. This stability in earnings per share may indicate that the company is managing its finances effectively.
However, the revenue for RASP saw a sharp decline to $0.00 million in the first quarter of 2024, compared to $0.00 million in the same period a year ago. This decrease in revenue could be a cause for concern as it may impact the company's overall financial health.

Actavia Life Sciences Inc

Actavia Life Sciences Inc Achieves Remarkable Stability with Balanced Books in Financial Q4 2023


As an observer of the financial landscape, it has become increasingly apparent that the life sciences industry is subject to a myriad of challenges. However, amidst this volatility, Actavia Life Sciences Inc has managed to achieve balanced books for the financial fourth quarter of 2023. This accomplishment holds great significance, particularly in light of the stark decline in revenue and the reported net loss.
The financial fourth quarter of 2023 proved to be a key defining period for Actavia Life Sciences Inc, as it successfully reached balanced books, with earnings per share staying steady at $0.00. While this result is unchanged from the previous year, it does mark a notable improvement from the previous financial reporting period. In a landscape where fluctuations are the norm, stability can often be seen as a sign of resilience and adaptability. Actavia's ability to maintain balance amidst increasing headwinds is commendable.

Rasna Therapeutics Inc

Rasna Therapeutics Inc's Revenue Soars while Earnings Remain Steady in Third Quarter of 2023



In the most recent fiscal period, Rasna Therapeutics Inc, a prominent biotechnology company, reported its financial results, revealing a mixed performance compared to the previous year. While the company achieved impressive revenue growth, its earnings per share remained steady. This article aims to provide an in-depth analysis of the financial results of Rasna Therapeutics Inc, offering investors and readers an understanding of the company's current standing.
Earnings per Share:
During the most recent fiscal period, Rasna Therapeutics Inc achieved earnings per share of $0.00. Although this figure remained unchanged from the previous reporting season, it is worth noting that the company successfully eliminated a loss incurred a year ago, where earnings per share stood at -$0.01. Maintaining a stable position in earnings per share can be an encouraging sign for stakeholders, reflecting the company's ability to deliver steady performance despite challenges faced.

Rasna Therapeutics Inc

Rasna Therapeutics Inc Generates Positive Revenue of $0.007888 Million, But Net Shortfall Raises Concerns

As a human invested in the stock market, one needs to be cautious when analyzing financial reports of companies and their performance. Recently, there have been a few announcements made about Rasna Therapeutics Inc, a company working in the field of biotechnology. The financial report for the second quarter of 2023 disclosed that the company generated $0.007888 million in revenue, which is a positive sign. However, the net shortfall of $-4.129 million in the same quarter is a cause for concern.
Investors should be aware that any fluctuations in revenue and net income can have a significant impact on the stock price of a company. In this case, even though the revenue generated by Rasna seems to be on the rise, it is essential to look at the net shortfall of $-4.129 million, which is a decrease compared to the previous year's quarter, where there was no shortfall.






 

Actavia Life Sciences Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com